Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Mitochondrial hypoxic stress induces widespread RNA editing by APOBEC3G in natural killer cells.

Sharma S, Wang J, Alqassim E, Portwood S, Cortes Gomez E, Maguire O, Basse PH, Wang ES, Segal BH, Baysal BE.

Genome Biol. 2019 Feb 21;20(1):37. doi: 10.1186/s13059-019-1651-1.

2.

Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment.

Theodoraki MN, Yerneni S, Sarkar SN, Orr B, Muthuswamy R, Voyten J, Modugno F, Jiang W, Grimm M, Basse PH, Bartlett DL, Edwards RP, Kalinski P.

Cancer Res. 2018 Aug 1;78(15):4292-4302. doi: 10.1158/0008-5472.CAN-17-3985. Epub 2018 May 31.

3.

Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells.

Goding SR, Yu S, Bailey LM, Lotze MT, Basse PH.

Clin Immunol. 2017 Apr;177:76-86. doi: 10.1016/j.clim.2016.06.013. Epub 2016 Jul 1.

4.

Cancer Stem Cells Protect Non-Stem Cells From Anoikis: Bystander Effects.

Kim SY, Hong SH, Basse PH, Wu C, Bartlett DL, Kwon YT, Lee YJ.

J Cell Biochem. 2016 Oct;117(10):2289-301. doi: 10.1002/jcb.25527. Epub 2016 Apr 4.

PMID:
26918647
5.

Exogenous activated NK cells enhance trafficking of endogenous NK cells to endometriotic lesions.

Montenegro ML, Ferriani RA, Basse PH.

BMC Immunol. 2015 Aug 29;16:51. doi: 10.1186/s12865-015-0105-0.

6.

The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells.

Gomez-Casal R, Bhattacharya C, Epperly MW, Basse PH, Wang H, Wang X, Proia DA, Greenberger JS, Socinski MA, Levina V.

Cancers (Basel). 2015 May 22;7(2):876-907. doi: 10.3390/cancers7020814.

7.

Viral infection of implanted meningeal tumors induces antitumor memory T-cells to travel to the brain and eliminate established tumors.

Gao Y, Whitaker-Dowling P, Barmada MA, Basse PH, Bergman I.

Neuro Oncol. 2015 Apr;17(4):536-44. doi: 10.1093/neuonc/nou231. Epub 2014 Sep 14.

8.

Relocation of CLIC1 promotes tumor cell invasion and colonization of fibrin.

Gurski LA, Knowles LM, Basse PH, Maranchie JK, Watkins SC, Pilch J.

Mol Cancer Res. 2015 Feb;13(2):273-80. doi: 10.1158/1541-7786.MCR-14-0249. Epub 2014 Sep 9.

9.

NK cells in the tumor microenvironment.

Larsen SK, Gao Y, Basse PH.

Crit Rev Oncog. 2014;19(1-2):91-105. Review.

10.

Novel nuclear localization of fatty acid synthase correlates with prostate cancer aggressiveness.

Madigan AA, Rycyna KJ, Parwani AV, Datiri YJ, Basudan AM, Sobek KM, Cummings JL, Basse PH, Bacich DJ, O'Keefe DS.

Am J Pathol. 2014 Aug;184(8):2156-62. doi: 10.1016/j.ajpath.2014.04.012. Epub 2014 Jun 5.

11.

Matrix metalloproteinases in cytotoxic lymphocytes impact on tumour infiltration and immunomodulation.

Edsparr K, Basse PH, Goldfarb RH, Albertsson P.

Cancer Microenviron. 2011 Dec;4(3):351-60. doi: 10.1007/s12307-010-0057-0. Epub 2010 Nov 27.

12.

Regenerated luminal epithelial cells are derived from preexisting luminal epithelial cells in adult mouse prostate.

Liu J, Pascal LE, Isharwal S, Metzger D, Ramos Garcia R, Pilch J, Kasper S, Williams K, Basse PH, Nelson JB, Chambon P, Wang Z.

Mol Endocrinol. 2011 Nov;25(11):1849-57. doi: 10.1210/me.2011-1081. Epub 2011 Sep 22.

13.

Merkel cell polyomavirus large T antigen disrupts lysosome clustering by translocating human Vam6p from the cytoplasm to the nucleus.

Liu X, Hein J, Richardson SC, Basse PH, Toptan T, Moore PS, Gjoerup OV, Chang Y.

J Biol Chem. 2011 May 13;286(19):17079-90. doi: 10.1074/jbc.M110.192856. Epub 2011 Mar 16.

14.

Zinc in innate and adaptive tumor immunity.

John E, Laskow TC, Buchser WJ, Pitt BR, Basse PH, Butterfield LH, Kalinski P, Lotze MT.

J Transl Med. 2010 Nov 18;8:118. doi: 10.1186/1479-5876-8-118. Review.

15.

Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models.

Zamboni WC, Eiseman JL, Strychor S, Rice PM, Joseph E, Zamboni BA, Donnelly MK, Shurer J, Parise RA, Tonda ME, Yu NY, Basse PH.

J Liposome Res. 2011 Mar;21(1):70-80. doi: 10.3109/08982101003754385. Epub 2010 Jun 9.

PMID:
20528623
16.

Effects of IL-2 on MMP expression in freshly isolated human NK cells and the IL-2-independent NK cell line YT.

Edsparr K, Speetjens FM, Mulder-Stapel A, Goldfarb RH, Basse PH, Lennernäs B, Kuppen PJ, Albertsson P.

J Immunother. 2010 Jun;33(5):475-81. doi: 10.1097/CJI.0b013e3181d372a0.

17.

Pharmacologic administration of interleukin-2.

Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, Zeh H, de Vera ME, Lotze MT.

Ann N Y Acad Sci. 2009 Dec;1182:14-27. doi: 10.1111/j.1749-6632.2009.05160.x.

PMID:
20074271
18.

IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors.

Sasaki K, Pardee AD, Qu Y, Zhao X, Ueda R, Kohanbash G, Bailey LM, Okada H, Muthuswamy R, Kalinski P, Basse PH, Falo LD, Storkus WJ.

J Immunother. 2009 Oct;32(8):793-802. doi: 10.1097/CJI.0b013e3181acec1e.

19.

Human NK cell lines migrate differentially in vitro related to matrix interaction and MMP expression.

Edsparr K, Johansson BR, Goldfarb RH, Basse PH, Nannmark U, Speetjens FM, Kuppen PJ, Lennernäs B, Albertsson P.

Immunol Cell Biol. 2009 Aug-Sep;87(6):489-95. doi: 10.1038/icb.2009.35. Epub 2009 May 12.

PMID:
19434071
20.

PTD-mediated loading of tumor-seeking lymphocytes with prodrug-activating enzymes.

Yang Q, Larsen SK, Mi Z, Robbins PD, Basse PH.

AAPS J. 2008 Dec;10(4):614-21. doi: 10.1208/s12248-008-9066-z. Epub 2008 Dec 23.

21.

Differential locomotion of long- and short-term IL-2-activated murine natural killer cells in a model matrix environment.

Albertsson P, Basse PH, Edsparr K, Kim MH, Goldfarb RH, Kitson RP, Lennernäs B, Nannmark U, Johansson BR.

Scand J Immunol. 2007 Oct;66(4):402-9. Erratum in: Scand J Immunol. 2007 Nov;66(5):601. Golfarb, R H [corrected to Goldfarb, R H].

22.

Cytokine gene therapy using adenovirally transduced, tumor-seeking activated natural killer cells.

Goding SR, Yang Q, Knudsen KB, Potter DM, Basse PH.

Hum Gene Ther. 2007 Aug;18(8):701-11.

PMID:
17678438
23.

Antitumor activity of NK cells.

Yang Q, Goding SR, Hokland ME, Basse PH.

Immunol Res. 2006;36(1-3):13-25. Review.

PMID:
17337762
24.

Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells.

Goding S, Yang Q, Mi Z, Robbins PD, Basse PH.

Cancer Gene Ther. 2007 May;14(5):441-50. Epub 2007 Feb 2.

PMID:
17273184
25.

Morphological appearance, content of extracellular matrix and vascular density of lung metastases predicts permissiveness to infiltration by adoptively transferred natural killer and T cells.

Yang Q, Goding S, Hagenaars M, Carlos T, Albertsson P, Kuppen P, Nannmark U, Hokland ME, Basse PH.

Cancer Immunol Immunother. 2006 Jun;55(6):699-707. Epub 2005 Jul 27.

PMID:
16047144
26.

Natural killer cells infiltrating colorectal cancer and MHC class I expression.

Sandel MH, Speetjens FM, Menon AG, Albertsson PA, Basse PH, Hokland M, Nagelkerke JF, Tollenaar RA, van de Velde CJ, Kuppen PJ.

Mol Immunol. 2005 Feb;42(4):541-6.

PMID:
15607811
27.

MRI detection of tumor in mouse lung using partial liquid ventilation with a perfluorocarbon-in-water emulsion.

Huang MQ, Basse PH, Yang Q, Horner JA, Hichens TK, Ho C.

Magn Reson Imaging. 2004 Jun;22(5):645-52.

PMID:
15172058
28.

NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity.

Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, Kuppen PJ.

Trends Immunol. 2003 Nov;24(11):603-9. Review.

PMID:
14596885
29.

Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases.

Yang Q, Hokland ME, Bryant JL, Zhang Y, Nannmark U, Watkins SC, Goldfarb RH, Herberman RB, Basse PH.

Int J Cancer. 2003 Jul 1;105(4):512-9.

30.

Cancer immunotherapy with interleukin-2-activated natural killer cells.

Basse PH, Whiteside TL, Herberman RB.

Mol Biotechnol. 2002 Jun;21(2):161-70.

PMID:
12059115
31.

Therapeutic activity of NK cells against tumors.

Basse PH, Whiteside TL, Chambers W, Herberman RB.

Int Rev Immunol. 2001 Jun;20(3-4):439-501. Review.

PMID:
11878512
32.

The microscopic anatomy of experimental rat CC531 colon tumour metastases: consequences for immunotherapy?

Hagenaars M, Ensink NG, Basse PH, Hokland M, Nannmark U, Eggermont AM, van de Velde CJ, Fleuren GJ, Kuppen PJ.

Clin Exp Metastasis. 2000;18(2):189-96.

PMID:
11235995
33.

Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer.

Kuppen PJ, van der Eb MM, Jonges LE, Hagenaars M, Hokland ME, Nannmark U, Goldfarb RH, Basse PH, Fleuren GJ, Hoeben RC, van de Velde CJ.

Histochem Cell Biol. 2001 Jan;115(1):67-72.

PMID:
11219610
34.

Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells.

Nannmark U, Hokland ME, Agger R, Christiansen M, Kjaergaard J, Goldfarb RH, Bagge U, Unger M, Johansson BR, Albertsson PA, Basse PH.

In Vivo. 2000 Sep-Oct;14(5):651-8.

PMID:
11125549
35.

Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors.

Bergman I, Basse PH, Barmada MA, Griffin JA, Cheung NK.

Cancer Immunol Immunother. 2000 Jul;49(4-5):259-66.

PMID:
10941909
36.

Secreted and membrane-associated matrix metalloproteinases of IL-2-activated NK cells and their inhibitors.

Kim MH, Kitson RP, Albertsson P, Nannmark U, Basse PH, Kuppen PJ, Hokland ME, Goldfarb RH.

J Immunol. 2000 Jun 1;164(11):5883-9.

37.

Methods for in vivo analyses of natural killer (NK) cells.

Chambers WH, Watkins SM, Basse PH.

Methods Mol Biol. 2000;121:95-114. Review. No abstract available.

PMID:
10818720
38.

Use of activated natural killer cells for tumor immunotherapy in mouse and human.

Basse PH, Whiteside TL, Herberman RB.

Methods Mol Biol. 2000;121:81-94. Review. No abstract available.

PMID:
10818719
39.

A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin.

Goldfarb RH, Koelemij R, Muirhead KA, Ohlsson-Wilhelm BM, Gray BD, Kuppen PJ, Basse PH, al-Atrash G, Kitson RP.

In Vivo. 2000 Jan-Feb;14(1):101-4.

PMID:
10757065
40.

Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals.

Kjaergaard J, Hokland ME, Agger R, Skovbo A, Nannmark U, Basse PH.

Cancer Immunol Immunother. 2000 Jan;48(10):550-60.

PMID:
10630307
41.

Activated natural killer cell tumor retention and cytokine production in colon tumor using a tissue-isolated model.

Ribeiro U Jr, Whiteside TL, Basse PH, Safatle-Ribeiro AV, Huneke CE, Posner MC.

J Surg Res. 1999 Mar;82(1):78-87.

PMID:
10068530
42.

Characteristics of tumor infiltration by adoptively transferred and endogenous natural-killer cells in a syngeneic rat model: implications for the mechanism behind anti-tumor responses.

Hagenaars M, Zwaveling S, Kuppen PJ, Ensink NG, Eggermont AM, Hokland ME, Basse PH, van de Velde CJ, Fleuren GJ, Nannmark U.

Int J Cancer. 1998 Dec 9;78(6):783-9.

43.

Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide.

Goldfarb RH, Ohashi M, Brunson KW, Kirii Y, Kotera Y, Basse PH, Kitson RP.

Anticancer Res. 1998 May-Jun;18(3A):1441-6.

PMID:
9673353
44.

Regional administration of natural killer cells in a rat hepatic metastasis model results in better tumor infiltration and anti-tumor response than systemic administration.

Hagenaars M, Ensink NG, Koelemij R, Basse PH, Eggermont AM, van de Velde CJ, Fleuren GJ, Kuppen PJ.

Int J Cancer. 1998 Jan 19;75(2):233-8.

45.
46.

Retention of adoptively transferred interleukin-2-activated natural killer cells in tumor tissue.

Ribeiro U Jr, Basse PH, Rosenstein M, Safatle-Ribeiro AV, Alhallak S, Goldfarb RH, Posner MC.

Anticancer Res. 1997 Mar-Apr;17(2A):1115-23.

PMID:
9137458
47.
48.

Microvessel origin and distribution in pulmonary metastases of B16 melanoma: implication for adoptive immunotherapy.

Nannmark U, Johansson BR, Bryant JL, Unger ML, Hokland ME, Goldfarb RH, Basse PH.

Cancer Res. 1995 Oct 15;55(20):4627-32.

49.
50.

Natural killer cells and gene therapy: potential of gene transfection for optimizing effector cell functions and for targeting gene products into tumor metastases.

Goldfarb RH, Whiteside TL, Basse PH, Lin WC, Vujanovic N, Herberman RB.

Nat Immun. 1994 Mar-Jun;13(2-3):131-40. Review.

PMID:
8173234

Supplemental Content

Loading ...
Support Center